🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,187

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

6,911 results for “Pharma” Clear

  1. Cyclobenzaprine HCl

    Takeda Pharmaceuticals International AG

    Neck Pain

    phase 3 small molecule completed

    1 trial

  2. Cyproterone acetate

    Takeda Pharmaceuticals International AG

    Adenocarcinoma, Prostate

    phase 3 small molecule completed

    1 trial

  3. Cytarabine

    Jazz Pharmaceuticals Ireland Limited

    Acute Myeloid Leukemia

    phase 3 small molecule active

    1 trial

  4. Cytarabine

    China SXT Pharmaceuticals

    AML

    phase 3 small molecule active

    3 trials

  5. DAPAGLIFLOZIN, PLACEBO DE DAPAGLIFLOZIN 10 mg

    Pari Pharma GmbH

    Cardiac failure

    phase 3 small molecule active

    1 trial

  6. DCC-3014, DCC-3014, Placebo to match DCC-3014

    Pharma Mar S.A.

    Tenosynovial Giant Cell Tumor

    phase 3 small molecule active

    1 trial

  7. DEGARELIX, GOSERELIN, TRIPTORELIN, LEUPRORELIN ACETATE, DEGARELIX, DEGARELIX, TRIPTORELIN , DEGARELIX, LEUPRORELIN ACETATE, TRIPTORELIN

    Cancer Prevention Pharma (Ireland) Limited

    very high risk localized or locally advanced prostate cancer

    phase 3 small molecule active

    1 trial

  8. DEXAMETHASONE , DARATUMUMAB, DARZALEX 1800 mg solution for injection, LENALIDOMIDE

    Pari Pharma GmbH

    Onco-hematology

    phase 3 small molecule active

    1 trial

  9. DEXAMETHASONE PHOSPHATE, Placebo of dexamethasone

    Pari Pharma GmbH

    respiratory distress due to upper airway obstruction in child

    phase 3 small molecule active

    1 trial

  10. DEXAMETHASONE, DEXAMETHASONE, DEXAMETHASONE

    Pari Pharma GmbH

    Multiple Myeloma Multiple myeloma (MM) is a B cell malignancy and is one of the most frequent primary neoplasms of the bone marrow

    phase 3 small molecule active

    1 trial

  11. DEXAMETHASONE, Dexamethasonfosfaat Accord 4 mg/ml oplossing voor injectie/infusie, Kyprolis 10 mg powder for solution for infusion, Paracetamol 1000mg Tablets, Imnovid 2 mg hard capsules, Imnovid 1 mg hard capsules, DARZALEX 1800 mg solution for injection, LYNOZYFIC 200 mg concentrate for solution for infusion, Dermodrin 30 mg/2 ml soluție injectabilă, Imnovid 3 mg hard capsules, DEXAMETHASONE, Co-Trimoxazole 80/400mg Tablets, Kyprolis 30 mg powder for solution for infusion, LYNOZYFIC 5 mg concentrate for s

    Pharma Mar S.A.

    Relapsed Refractory Multiple Myeloma

    phase 3 small molecule active

    1 trial

  12. DEXAMETHASONE, Xtandi - 40 mg soft capsules, PF-06821497, DEXAMETHASONE, PF-06821497, PREDNISOLONE, DOCETAXEL

    Pfizer Ireland Pharmaceuticals Unlimited Company

    METASTATIC CASTRATION RESISTANT PROSTATE CANCER

    phase 3 small molecule active

    1 trial

  13. DEXMEDETOMIDINE , 18F-DPA-714

    Pari Pharma GmbH

    Patients who survive a COVID ARDS in intensive care must be weaned off invasive mechanical ventilation as quickly as possible. 60% of these patients present with intensive care delirium, a serious event that causes excess mortality and potential acute and late complications, since 30% of patients who present with delirium develop cognitive sequelae. Severe neuroinflammation is considered to be one of the main pathophysiological mechanisms causing delirium during ventilatory weaning. In addition to its sedative properties, dexmedetomidine has neuroprotective effects. In certain experimental models, it reduces cerebral inflammation by acting directly on the microglial phenotype. The role of this chronic neuroinflammatory state on cognitive capacity and reserve is beginning to emerge in the literature, regardless of the initial stress (surgery, head injury or Alzheimer's-type dementia), and is therefore capable of influencing patients' quality of life. The assessment of this neuroinflammation using non-invasive tools would appear to be of prime importance in the management of post-COVID neuro injured patients, as well as the evaluation of potential neuroprotective agents such as dexmedetomidine.

    phase 3 small molecule active

    1 trial

  14. DOCETAXEL

    Pfizer Ireland Pharmaceuticals Unlimited Company

    Non-Small Cell Lung Cancer (NSCLC)

    phase 3 small molecule active

    1 trial

  15. DOXORUBICIN, EPIRUBICIN, CISPLATIN, OPDIVO 10 mg/mL concentrate for solution for infusion., MITOMYCIN, LIPIODOL ULTRA FLUIDE 480 mg/ml, solution injectable, IDARUBICIN

    Cancer Prevention Pharma (Ireland) Limited

    Intermediate stage Hepatocellular carcinoma

    phase 3 small molecule active

    1 trial

  16. DOXORUBICIN, Pralatrexate, PREDNISONE, Belinostat, VINCRISTINE SULFATE, CYCLOPHOSPHAMIDE

    Pharma Mar S.A.

    Peripheral T-Cell Lymphoma

    phase 3 small molecule active

    1 trial

  17. DOXYCYCLINE SANDOZ 100 mg, comprimé sécable, EXTENCILLINE 2,4 MUI, poudre et solvant pour suspension injectable IM

    Pari Pharma GmbH

    early syphilis

    phase 3 small molecule active

    1 trial

  18. DR-1011

    Teva Pharma GmbH

    Contraception

    phase 3 small molecule completed

    1 trial

  19. DR-102

    Teva Pharma GmbH

    Contraception

    phase 3 small molecule completed

    1 trial

  20. DR-1021

    Teva Pharma GmbH

    Contraception

    phase 3 small molecule completed

    1 trial

  21. DR-1021

    Teva Pharma GmbH

    Healthy

    phase 3 small molecule completed

    1 trial

  22. DR-103

    Teva Pharma GmbH

    Pregnancy Prevention

    phase 3 small molecule completed

    1 trial

  23. DR-104

    Teva Pharma GmbH

    Emergency Contraception

    phase 3 small molecule completed

    1 trial

  24. DR-2011

    Teva Pharma GmbH

    Infertility

    phase 3 small molecule completed

    2 trials

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources